

### III. In the Specification (Clean Sheet)

(Page 1, lines 3-5)

#### Field of the Invention

NE.

The present invention relates to an equine abortion virus mutant, a process for the preparation of said mutant, use of said mutant and live vaccines derived from said mutant.

(Page 1, lines 6-18)

#### Background of the Invention

Equine abortion virus (EHV-1), a herpes virus, is a major equine pathogen responsible for viral-induced abortion, neurological disease such as paresis, infections of the upper respiratory tract, and neonatal foal disease (NFD). NFD results from close to term transplacental infection of fetuses, which are born weak with severe respiratory disease and some with jaundice due to liver infection by EHV-1. These animals usually die within a few days after birth. Equine rhinopneumonitis virus (EHV-4) is the major cause of acute respiratory tract disease ("rhinopneumonitis") and infects most horses during their first two years of life. Rhinopneumonitis is characterized by fever, anorexia, and profuse serous nasal discharge that later becomes mucopurulent. On rare occasions EHV4 infection causes abortion in pregnant mares. Furthermore EHV1 and EHV4 establish persistent, lifelong latent infections.

Upon reactivation the viruses cause recurrent disease, accompanied by virus shedding and transmission to other animals.

(Page 1, lines 27)

### Summary of the Invention

The present invention provides for such vaccines.

(Page 2, lines 15-21)

### Detailed Description

For the purpose of this invention, a temperature sensitive mutant is defined as a mutant virus which has an impaired growth at or above a certain temperature at which the wild type has a normal growth. The EHV-1 ts mutants according to the present invention are characterized in that they are temperature sensitive at the body temperature of the host animal. The EHV-1 ts mutants of the present invention do not replicate above a temperature of 38.5 to 39.0°C. Preferably the EHV-1 ts mutants according to the invention do not replicate at a temperature of 38.5°C.

**IV. In the Specification (Marked Version)**

Please insert "Field of the Invention", as a new line,  
at line 3, page 1.

Please insert "Background of the Invention", as a new  
line, at line 6 of page 1.

Please insert "Summary of the Invention", as a new line,  
at line 27 of page 1.


Please insert "Detailed Description", as a new line, at  
line 15 of page 2.-

**V. Remarks**

Pursuant to 35 USC § 371, applicant is filing herewith the National Fee provided in § 41(a), a copy of the International Application, an Oath or Declaration of the Inventor, an Assignment, a Preliminary Amendment, an Information Disclosure Statement, PTO Form 1449 and search report with cited references. Applicant respectfully requests entry into the National Stage by recording this application appropriate status and entry of the preliminary amendment.

In the event any fees are required with this paper, please charge our Deposit Account No. 02-2334.

Respectfully submitted,



William P. Ramey III  
Patent Counsel  
Registration No. 44,295

Attorney Docket NO. I-99486 US

Intervet Inc Patent Department  
Akzo Nobel  
405 State Street  
P.O. Box 318  
Millsboro, DE 19966  
Tel: (302) 933-4034  
Fax: (302) 933-4013

WPR:kmm